New update updates on Anaphylaxis management
Reading File
Searching PubMed
anaphylaxis management guidelines
Searching the Web
anaphylaxis management guidelines 2024 2025 updates
Finding Sources
Reading Article
Reading Article
Reading Web Page
anaphylaxis management guidelines updates epinephrine treatment
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed
anaphylaxis epinephrine autoinjector observation discharge biphasic
Reading File
I now have comprehensive information to provide a thorough, up-to-date answer. Let me compile everything.
Anaphylaxis Management: Updated Guidelines (2023-2026)
Key Guideline Updates
The most significant recent update is the 2023 AAAAI/ACAAI Joint Task Force on Practice Parameters (JTFPP) Anaphylaxis Practice Parameter, with further pearls published in 2025 (PMID: 39254667). This supersedes earlier guidance. Here is a full breakdown.
1. Diagnosis Criteria
Anaphylaxis remains a clinical diagnosis. The WAO/NIAID criteria define it as highly likely when any ONE of these two is met:
- Criterion 1: Acute onset of illness with skin/mucosal involvement AND at least one of: respiratory compromise, reduced BP/end-organ dysfunction
- Criterion 2: Two or more of the following after likely allergen exposure: skin/mucosal symptoms, respiratory compromise, reduced BP, persistent GI symptoms
The 2023 JTFPP emphasizes that diagnostic certainty should NEVER delay epinephrine - treat on suspicion.
2. First-Line Treatment: Epinephrine (Adrenaline)
Still the cornerstone - no change here, but emphasis strengthened
| Parameter | Recommendation |
|---|---|
| Drug | Epinephrine 1:1,000 (1 mg/mL) |
| Route | Intramuscular (IM) into the anterolateral mid-thigh - faster absorption than deltoid |
| Adult dose | 0.3-0.5 mg IM |
| Pediatric dose | 0.01 mg/kg IM (max 0.5 mg) |
| Repeat | Every 5 minutes if no improvement |
New from 2023 JTFPP - Pediatric autoinjector dosing update:
- Children <15 kg: Clinician may prescribe either 0.1 mg OR 0.15 mg autoinjector (previously 0.15 mg only)
- Children 15-25 kg: 0.15 mg autoinjector
- Children ≥25 kg: 0.3 mg autoinjector (threshold lowered from 30 kg)
- Adults >50 kg: 0.3 mg or 0.5 mg
Cross-guideline consensus (AAAAI/ACAAI, EAACI, Resuscitation Council UK, 2025 FDA document):
"Immediate epinephrine - without waiting for diagnostic certainty - is the standard of care and the strongest predictor of survival."
A 2026 systematic review (PMID: 41701644, 28 studies, 20 countries) confirmed that delayed epinephrine >30 minutes after symptom onset was consistently associated with fatal outcomes.
3. Positioning
Updated emphasis: Lay the patient flat with legs elevated (supine position). If breathing difficulty is present, allow semi-reclined with legs elevated. Do not allow the patient to stand up suddenly - "fatal posture" (upright or sudden standing) is an independent risk factor for death as it exacerbates hemodynamic collapse.
4. Adjunct Treatments (Second-Line Only)
IV Fluids
- Adults: 1-2 L normal saline rapidly via large-bore IV (16G)
- Pediatrics: 20-30 mL/kg boluses
- Large volumes (up to 2-7 L) may be needed; monitor for overload in cardiac/renal patients
Antihistamines (H1 + H2)
- Must NEVER be used as sole or initial treatment
- Helpful only for cutaneous symptoms (urticaria, pruritus, flushing) as adjuncts
- Diphenhydramine 25-50 mg IV/IM (adult); ranitidine/famotidine as H2 blocker
Corticosteroids
- No immediate effect on anaphylaxis
- No strong evidence they prevent biphasic reactions (this is an important 2023 update - previously often given routinely)
- Optional adjunct only; never precede epinephrine
- If used: hydrocortisone 200 mg IV (adult) or methylprednisolone 1-2 mg/kg
Bronchodilators
- Salbutamol (albuterol) via nebulizer for bronchospasm after epinephrine
Glucagon (special circumstance)
- For patients on beta-blockers who fail to respond to epinephrine
- Adult dose: 1-5 mg IV followed by infusion 5-15 mcg/min
- Pediatric: 20-30 mcg/kg (max 1 mg)
- Pre-medicate with antiemetic (nausea/vomiting common)
5. Refractory Anaphylaxis
If no response after 2+ doses of IM epinephrine:
- IV epinephrine infusion: 0.1-1 mcg/kg/min, titrate to response
- Vasopressors (norepinephrine, vasopressin, methoxamine) if epinephrine infusion fails
- Methylene blue: Considered for refractory vasodilatory shock
- Consider intubation early if airway compromise is progressing
6. Beta-Blocker / ACE Inhibitor Interactions (2023 JTFPP Update)
Important new stance: For patients who require beta-blockers or ACE inhibitors for cardiac disease, the 2023 JTFPP now states:
"Discontinuing or changing beta-blockers and/or ACE inhibitors may pose a larger risk for worsened cardiovascular disease compared with the risk for severe anaphylaxis with medication continuation."
This is a shift from the older blanket recommendation to stop these drugs. Shared decision-making is now emphasized.
7. Observation & Discharge (Updated Criteria)
| Category | Observation Period |
|---|---|
| Mild-moderate, complete symptom resolution, 1 dose epinephrine | Minimum 1 hour (with caregiver comfort and EMS access) |
| Standard risk | 4-6 hours |
| High risk for biphasic reaction | 6+ hours or hospitalize |
High-risk for biphasic features (admit or extend observation):
- Hypotension or wide pulse pressure at presentation
- Unknown trigger
-
1 dose of epinephrine required
- Cutaneous involvement
- History of prior anaphylaxis
- Delayed epinephrine administration
- Protracted initial reaction, airway involvement, or poor social support
Key 2023 update: EMS activation may not be required in patients who experience prompt, complete symptom resolution after epinephrine and caregivers are comfortable with observation at home. This represents a more flexible community-management approach.
8. Predictors of Fatal Anaphylaxis (2026 Systematic Review - PMID: 41701644)
From 28 studies across 20 countries:
- Asthma (most consistent comorbidity)
- Cardiovascular comorbidities
- Age ≥65 years
- Delayed epinephrine (>30 min from symptom onset or absent prehospital)
- Trigger-specific: peanuts and cow's milk in children; perioperative medications in older adults
Real-world data shows only ~41% of patients who carry an epinephrine autoinjector actually use it during a reaction - a major ongoing patient education target.
9. Discharge Planning (All Guidelines Agree)
Every patient discharged must receive:
- Prescription for 2 epinephrine autoinjectors (carry two at all times)
- Written action plan (ASCIA/ACAAI format)
- Education on trigger avoidance, recognition, and when to use autoinjector
- Referral to allergist/immunologist for formal evaluation and immunotherapy if appropriate (e.g., venom allergy, milk/egg allergy - OIT options available)
- Medical alert identification recommended
10. Novel/Emerging Therapies (2025+)
- Omalizumab (anti-IgE): Now being used in select patients to reduce risk of severe community anaphylaxis, particularly for food allergy and chronic spontaneous urticaria
- Oral immunotherapy (OIT): Expanding for peanut, milk, and tree nut - reduces severity of accidental exposure reactions
- Sublingual immunotherapy (SLIT): Growing evidence base for food allergens
- Alpha-gal syndrome: Increasingly recognized trigger (tick-sensitized meat allergy) - guidelines now include this in differential
Summary of What's Changed vs. Older Guidelines
| Area | Old Guidance | 2023-2026 Update |
|---|---|---|
| Pediatric autoinjector <15 kg | 0.15 mg only | 0.1 mg OR 0.15 mg acceptable |
| Pediatric ≥25 kg threshold | ≥30 kg for 0.3 mg | Lowered to ≥25 kg |
| Corticosteroids for biphasic prevention | Routinely given | Not strongly supported; optional only |
| Beta-blocker/ACEi continuation | Often stopped | Continue if cardiac risk of stopping > anaphylaxis risk |
| Minimum observation (mild/resolved) | 4-6 hours | 1 hour may be sufficient in low-risk with resolved symptoms |
| EMS activation after resolution | Always required | Not mandatory if prompt resolution and caregiver comfort |
Sources:
- Rosen's Emergency Medicine, 9e, pp. 2386-2394
- Goldman-Cecil Medicine, International Ed., pp. 2697-2700
- 2023 JTFPP Anaphylaxis Practice Parameter (PMID: 39254667)
- Predictors of Fatal Anaphylaxis systematic review, 2026 (PMID: 41701644)
- FDA/AAAAI/ACAAI/EAACI/Resuscitation Council UK consensus document, Nov 2025
This is a shared conversation. Sign in to Orris to start your own chat.